glioblastoma

Using single-cell and bulk RNA sequence data, investigators identified four pathway-based GBM subtypes, including a mitochondrial subtype that appears to respond to related inhibitors.

By screening more than 1,500 drugs against patient-derived glioblastoma cells, researchers tracked down tumor alterations with apparent ties to proteasome inhibitor response.

Researchers saw similar cell hierarchies and progenitor cell clusters when comparing single-cell RNA sequencing data for cells from glioblastoma tumors and developing brains.

Researchers analyzed evolutionarily constrained non-coding mutations in genome sequences from dozens of glioblastoma patients, identifying regulation-related changes.

Presentations at the American Society of Clinical Oncology's virtual annual meeting included new findings relevant to both blood- and spinal fluid-based approaches.